Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stake Lowered by Bellevue Group AG

Bellevue Group AG trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 15.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,055,874 shares of the company’s stock after selling 374,626 shares during the period. Neurocrine Biosciences comprises approximately 4.3% of Bellevue Group AG’s portfolio, making the stock its 3rd biggest holding. Bellevue Group AG owned about 2.04% of Neurocrine Biosciences worth $283,546,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Neurocrine Biosciences by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock valued at $1,369,673,000 after buying an additional 220,598 shares during the last quarter. Brown Advisory Inc. lifted its stake in Neurocrine Biosciences by 2.2% in the fourth quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock valued at $146,703,000 after acquiring an additional 23,831 shares during the last quarter. Los Angeles Capital Management LLC grew its position in Neurocrine Biosciences by 66.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock worth $121,007,000 after acquiring an additional 364,986 shares in the last quarter. Vestal Point Capital LP acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth $105,408,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Neurocrine Biosciences by 10.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 686,835 shares of the company’s stock valued at $90,497,000 after purchasing an additional 63,568 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. HC Wainwright increased their target price on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Morgan Stanley boosted their target price on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, July 12th. Wedbush reiterated an “outperform” rating and set a $152.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, May 29th. Barclays boosted their price objective on shares of Neurocrine Biosciences from $150.00 to $169.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. Finally, Citigroup raised their target price on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $154.08.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Gary A. Lyons sold 12,500 shares of Neurocrine Biosciences stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $135.63, for a total transaction of $1,695,375.00. Following the completion of the transaction, the director now directly owns 116,947 shares of the company’s stock, valued at $15,861,521.61. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 273 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $140.55, for a total value of $38,370.15. Following the transaction, the insider now directly owns 7,507 shares in the company, valued at $1,055,108.85. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gary A. Lyons sold 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $135.63, for a total transaction of $1,695,375.00. Following the sale, the director now directly owns 116,947 shares of the company’s stock, valued at approximately $15,861,521.61. The disclosure for this sale can be found here. Insiders have sold 80,709 shares of company stock worth $11,009,150 over the last three months. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Trading Up 0.5 %

NASDAQ NBIX traded up $0.70 on Friday, reaching $146.80. The company’s stock had a trading volume of 744,764 shares, compared to its average volume of 631,030. Neurocrine Biosciences, Inc. has a 52 week low of $99.36 and a 52 week high of $150.39. The firm has a market cap of $14.77 billion, a PE ratio of 40.44 and a beta of 0.37. The business has a 50-day moving average price of $139.16 and a 200 day moving average price of $137.97.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. The company had revenue of $515.30 million during the quarter, compared to the consensus estimate of $512.21 million. Analysts anticipate that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.